Sangamo Therapeutics (SGMOQ) FCF Margin (2010 - 2025)

Sangamo Therapeutics' FCF Margin history runs 16 years deep, the most recent figure standing at 171.61% for Q4 2025.

• On a quarterly basis, FCF Margin fell 12241.0% year-over-year to 171.61% in Q4 2025; TTM through Dec 2025 was 246.03%, a 12731.0% decrease from a year earlier, with the FY2025 full-year figure at 246.03%, down 12946.0% from the prior year.
• FCF Margin climbed to 171.61% in Q4 2025 per SGMOQ's latest filing, from 4916.01% in the prior quarter.
• Across five years, FCF Margin topped out at 23.01% in Q3 2024 and bottomed at 10212.68% in Q1 2024.
• The 5-year median for FCF Margin is 234.77% (2021), against an average of 1438.37%.
• Across the five-year window, FCF Margin slumped 1016425 bps in 2024 and surged 980282 bps in 2025, its largest moves.
• Year by year, FCF Margin stood at 198.57% in 2021, then fell by 19 bps to 236.96% in 2022, then sank by 897 bps to 2361.8% in 2023, then surged by 98 bps to 49.2% in 2024, then slumped by 249 bps to 171.61% in 2025.
• Per Business Quant, the three latest SGMOQ FCF Margin figures stand at 171.61% (Q4 2025), 4916.01% (Q3 2025), and 98.04% (Q2 2025).